Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Study context
- Population
- Participants with history of atherosclerotic cardiovascular disease (ASCVD) and/or underlying heterozygous familial hypercholesterolemia (HeFH) whose low-density lipoprotein cholesterol (LDL-C) is not adequately controlled despite maximally tolerated lipid-modifying therapiesBROADWAY 2,532
- Planned comparison
- Obicetrapib 10 mg vs placebo, on top of maximally tolerated lipid-modifying therapies
- Primary endpoint
- Percent change in LDL-C from baseline
- Follow-up
- Day 84
Methodological detailsBROADWAY and BROOKLYN, placebo-controlled, double-blind, Phase III, 2:1 randomisation, ongoing, Results from both trials anticipated in 2024
- BROADWAY and BROOKLYN
- Placebo-controlled
- Double-blind
- Phase III
- 2:1 randomisation
- Ongoing
- Results from both trials anticipated in 2024
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. Published 4 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →